CLINICAL_TRIALS
trial_result
· 2017-03-31
Clinical Trial Update: Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 3]
Summary
Phase 3 trial evaluating afatinib in non-small cell lung cancer patients with EGFR mutations has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2017-03-31